罗特西普治疗非输血依赖型β地中海贫血的疗效与安全性:BEYOND研究的长期结果
BEYOND研究最终分析报告罗特西普在非输血依赖型β地中海贫血中的长期疗效与安全性,额外随访约2.2年。罗特西普组94.8% vs 安慰剂组22.4%的患者在任意12周区间内血红蛋白较基线平均升高≥1.0 g/dL,平均缓解持续时间分别为1136.0天与203.3天,安全性特征与既往一致,未发现新的安全性信号。
要点
- 罗特西普组94.8% vs 安慰剂组22.4%的患者在任意12周区间内血红蛋白较基线平均升高≥1.0 g/dL。
- 平均缓解持续时间罗特西普组1136.0天 vs 安慰剂组203.3天。
- 罗特西普组最常见治疗中出现的不良事件为头痛45.8% vs 安慰剂组20.4%、骨痛43.8% vs 6.1%、背痛39.6% vs 12.2%、关节痛38.5% vs 16.3%。
核心结论
- 罗特西普使非输血依赖型β地中海贫血患者的血红蛋白水平持续升高,治疗时间最长约4.6年,安全性特征一致且未发现新的安全性信号。
- 罗特西普是非输血依赖型β地中海贫血患者有价值的治疗选择,可满足对贫血有效长期治疗的需求。
研究设计与样本
- BEYOND研究为2期随机双盲安慰剂对照试验(ClinicalTrials.gov标识符NCT03342404),本文报告其最终分析的长期疗效与安全性结果,额外随访26个月(约2.2年)。
- 罗特西普组中位治疗持续时间202.8周,安慰剂组61.1周。
主要发现
- 罗特西普组94.8% vs 安慰剂组22.4%的患者在任意12周区间内达到血红蛋白较基线平均升高≥1.0 g/dL,平均缓解持续时间分别为1136.0天与203.3天。
- 患者报告的疲倦和乏力在罗特西普治疗下显示持续改善。
- 罗特西普组最常见的治疗中出现的不良事件为头痛(45.8% vs 安慰剂组20.4%)、骨痛(43.8% vs 6.1%)、背痛(39.6% vs 12.2%)和关节痛(38.5% vs 16.3%)。
- 治疗中出现的髓外造血事件在罗特西普组和安慰剂组分别报告于12例(9.0%)和2例(4.1%)患者,但治疗暴露时间差异使比较无法提供有效信息。
- 罗特西普组报告血栓栓塞事件的4例患者均具有>1项危险因素。
临床怎么用
- 原文结论认为罗特西普是非输血依赖型β地中海贫血患者有价值的治疗选择,可满足对贫血有效长期治疗的需求。
局限性
- 治疗中出现的髓外造血事件在罗特西普组和安慰剂组分别报告于12例(9.0%)和2例(4.1%)患者,但治疗暴露时间差异使比较无法提供有效信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic anemia due to non-transfusion-dependent β-thalassemia (NTDT) can result in clinical morbidities, particularly with inadequate management. Luspatercept was previously shown to improve hemoglobin levels in patients with NTDT in the phase 2, randomized, double-blind, placebo-controlled BEYOND trial (ClinicalTrials.gov identifier: NCT03342404). Here, we report long-term efficacy and safety results from the final analysis of BEYOND spanning an additional 26 months (∼2.2 years) of follow-up. Median treatment duration was 202.8 weeks for luspatercept and 61.1 weeks for placebo. Overall, 94.8% and 22.4% of patients in the luspatercept and placebo arms, respectively, achieved a mean hemoglobin increase from baseline ≥1.0 g/dL during any 12-week interval, with mean durations of response of 1136.0 and 203.3 days, respectively. Patient-reported tiredness and weakness showed sustained improvement with luspatercept treatment. The most common treatment-emergent adverse events in the luspatercept group were headache (45.8% vs 20.4% with placebo), bone pain (43.8% vs 6.1%), back pain (39.6% vs 12.2%), and arthralgia (38.5% vs 16.3%). Treatment-emergent extramedullary hematopoiesis events were reported in 12 (9.0%) and 2 (4.1%) patients receiving luspatercept and placebo, respectively, although differences in treatment exposures prevented informative comparisons. Of the 4 patients receiving luspatercept who reported thromboembolic events, all had >1 risk factor. These results show that luspatercept led to a sustained increase in hemoglobin levels in patients with NTDT for up to ∼4.6 years of treatment, with a consistent safety profile and no new safety findings. Luspatercept is a valuable treatment option for patients with NTDT, addressing the need for effective long-term treatment of anemia. This trial was registered at www.clinicaltrials.gov as #NCT03342404.
引用
- Taher AT, Viprakasit V, Kattamis A, et al. Efficacy and safety of luspatercept in non-transfusion-dependent β-thalassemia: long-term results from the BEYOND study. Blood Adv. 2025. PMID: 40875596. doi:10.1182/bloodadvances.2025016554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。